|
1
|
Mele A, Pulsoni A, Bianco E, Musto P,
Szklo A, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Liso V, et
al: Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian
multicenter case-control study. Blood. 102:996–999. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ennishi D, Maeda Y, Niitsu N, Kojima M,
Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu
Y, et al: Hepatic toxicity and prognosis in hepatitis C
virus-infected patients with diffuse large B-cell lymphoma treated
with rituximab-containing chemotherapy regimens: a Japanese
multicenter analysis. Blood. 116:5119–5125. 2010. View Article : Google Scholar
|
|
3
|
De Vita S, Sacco C, Sansonno D, Gloghini
A, Dammacco F, Crovatto M, Santini G, Dolcetti R, Boiocchi M,
Carbone A and Zagonel V: Characterization of overt B-cell lymphomas
in patients with hepatitis C virus infection. Blood. 90:776–782.
1997.PubMed/NCBI
|
|
4
|
Pioltelli P, Zehender G, Monti G,
Monteverde A and Galli M: HCV and non-Hodgkin lymphoma. Lancet.
347:624–625. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsuo K, Kusano A, Sugumar A, Nakamura S,
Tajima K and Mueller NE: Effect of hepatitis C virus infection on
the risk of non-Hodgkin’s lymphoma: a meta-analysis of
epidemiological studies. Cancer Sci. 95:745–752. 2004.
|
|
6
|
Gisbert JP, Garcia-Buey L, Pajares JM and
Moreno-Otero R: Prevalence of hepatitis C virus infection in B-cell
non-Hodgkin’s lymphoma: systematic review and meta-analysis.
Gastroenterology. 125:1723–1732. 2003.
|
|
7
|
Izumi T, Sasaki R, Tsunoda S, Akutsu M,
Okamoto H and Miura Y: B cell malignancy and hepatitis C virus
infection. Leukemia. 11:516–518. 1997.PubMed/NCBI
|
|
8
|
Galli M, Pioltelli P, Zehender G, Monti G
and Monteverde A: HCV and lymphomagenesis. Lancet. 348:2751996.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hartridge-Lambert SK, Stein EM, Markowitz
AJ and Portlock CS: Hepatitis C and non-Hodgkin lymphoma: the
clinical perspective. Hepatology. 55:634–641. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawatani T, Suou T, Tajima F, Ishiga K,
Omura H, Endo A, Ohmura H, Ikuta Y, Idobe Y and Kawasaki H:
Incidence of hepatitis virus infection and severe liver dysfunction
in patients receiving chemotherapy for hematologic malignancies.
Eur J Haematol. 67:45–50. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zuckerman E, Zuckerman T, Douer D, Qian D
and Levine AM: Liver dysfunction in patients infected with
hepatitis C virus undergoing chemotherapy for hematologic
malignancies. Cancer. 83:1224–1230. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Besson C, Canioni D, Lepage E, Pol S,
Morel P, Lederlin P, van Hoof A, Tilly H, Gaulard P, Coiffier B, et
al: Groupe d’Etude des Lymphomes de l’Adulte Programs:
Characteristics and outcome of diffuse large B-cell lymphoma in
hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe
d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol.
24:953–960. 2006.
|
|
13
|
Arcaini L, Merli M, Passamonti F, Bruno R,
Brusamolino E, Sacchi P, Rattotti S, Orlandi E, Rumi E, et al:
Impact of treatment-related liver toxicity on the outcome of
HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 85:46–50.
2009.PubMed/NCBI
|
|
14
|
Tobinai K and Hotta T: Clinical trials for
malignant lymphoma in Japan. Jpn J Clin Oncol. 34:369–378. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lake-Bakaar G, Dustin L, McKeating J,
Newton K, Freeman V and Frost SD: Hepatitis C virus and alanine
aminotransferase kinetics following B-lymphocyte depletion with
rituximab: evidence for a significant role of humoral immunity in
the control of viremia in chronic HCV liver disease. Blood.
109:845–846. 2007. View Article : Google Scholar
|
|
16
|
Tsutsumi Y, Kanamori H, Mori A, Tanaka J,
Asaka M, Imamura M and Masauzi N: Reactivation of hepatitis B virus
with rituximab. Expert Opin Drug Saf. 4:599–608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai MS, Chao TY, Kao WY, Shyu RY and Liu
TM: Delayed hepatitis B virus reactivation after cessation of
preemptive lamivudine in lymphoma patients treated with rituximab
plus CHOP. Ann Hematol. 83:769–774. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Niitsu N, Hagiwara Y, Tanae K, Kohri M and
Takahashi N: Prospective analysis of hepatitis B virus reactivation
in patients with diffuse large B-cell lymphoma after rituximab
combination chemotherapy. J Clin Oncol. 28:5097–5100. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Renzo A, Perna F, Persico M, Notaro R,
Mainolfi C, de Sio I, Ciancia G, Picardi M, Del Vecchio L, Pane F
and Rotoli B: Excellent prognosis and prevalence of HCV infection
of primary hepatic and splenic non-Hodgkin’s lymphoma. Eur J
Haematol. 81:51–57. 2008.PubMed/NCBI
|
|
20
|
Harris NL, Jaffe ES, Diebold J, Flandrin
G, Muller-Hermelink HK, Vardiman J, Lister TA and Bloomfield CD:
World Health Organization classification of neoplastic diseases of
the hematopoietic and lymphoid tissues: report of the Clinical
Advisory Committee meeting-Airlie House, Virginia, November 1997. J
Clin Oncol. 17:3835–3849. 1999.
|
|
21
|
Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba
K, Orito E, Mukaide M, Williams R and Lau JY: New hepatitis C virus
(HCV) genotyping system that allows for identification of HCV
genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol.
35:201–207. 1997.PubMed/NCBI
|
|
22
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the Committee on Hodgkin’s
Disease Staging Classification. Cancer Res. 31:1860–1861. 1971.
|
|
23
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai
K, Vose JM, Connors JM, Federico M and Diehl V: International
Harmonization Project on Lymphoma: revised response criteria for
malignant lymphoma. J Clin Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Labarga P, Soriano V, Vispo ME, Pinilla J,
Martin-Carbonero L, Castellares C, Casado R, Maida I, Garcia-Gasco
P and Barreiro P: Hepatotoxicity of antiretroviral drugs is reduced
after successful treatment of chronic hepatitis C in HIV-infected
patients. J Infect Dis. 196:670–676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
[No authors listed]. A predictive model
for aggressive non-Hodgkin’s lymphoma. The International
Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med.
329:987–994. 1993.
|
|
26
|
Visco C, Arcaini L, Brusamolino E,
Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A,
Lazzarino M, et al: Distinctive natural history in hepatitis C
virus positive diffuse large B-cell lymphoma: analysis of 156
patients from northern Italy. Ann Oncol. 17:1434–1440. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshida H, Shiratori Y, Moriyama M,
Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, et
al: Interferon therapy reduces the risk for hepatocellular
carcinoma: national surveillance program of cirrhotic and
noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study
Group. Ann Intern Med. 131:174–181. 1999. View Article : Google Scholar
|
|
28
|
Nishiguchi S, Shiomi S, Nakatani S, Takeda
T, Fukuda K, Tamori A, Habu D and Tanaka T: Prevention of
hepatocellular carcinoma in patients with chronic active hepatitis
C and cirrhosis. Lancet. 357:196–197. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
La Mura V, De Renzo A, Perna F, D’Agostino
D, Masarone M, Romano M, Bruno S, Torella R and Persico M:
Antiviral therapy after complete response to chemotherapy could be
efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol.
49:557–563. 2008.PubMed/NCBI
|
|
30
|
Pellicelli AM, Marignani M, Zoli V, Romano
M, Morrone A, Nosotti L, Barbaro G, Picardi A, Gentilucci UV,
Remotti D, et al: Hepatitis C virus-related B cell subtypes in non
Hodgkin’s lymphoma. World J Hepatol. 3:278–284. 2011.PubMed/NCBI
|
